AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Kalyan Kumar Pasunooti, 5-Methylisoxazole-3-carboxamide-Directed Palladium-Catalyzed γ-C(sp3)–H Acetoxylation and Application to the Synthesis of γ-Mercapto Amino Acids for Native Chemical Ligation

 Uncategorized  Comments Off on Kalyan Kumar Pasunooti, 5-Methylisoxazole-3-carboxamide-Directed Palladium-Catalyzed γ-C(sp3)–H Acetoxylation and Application to the Synthesis of γ-Mercapto Amino Acids for Native Chemical Ligation
Oct 132018
 
Abstract Image

Palladium-catalyzed acetoxylation of the primary γ-C(sp3)–H bonds in the amino acids Val, Thr, and Ile was achieved using a newly discovered 5-methylisoxazole-3-carboxamide directing group. The γ-acetoxylated α-amino acid derivatives could be easily converted to γ-mercapto amino acids, which are useful for native chemical ligation (NCL). The first application of NCL at isoleucine in the semisynthesis of a Xenopus histone H3 protein was also demonstrated.

5-Methylisoxazole-3-carboxamide-Directed Palladium-Catalyzed γ-C(sp3)–H Acetoxylation and Application to the Synthesis of γ-Mercapto Amino Acids for Native Chemical Ligation

School of Biological Sciences, Nanyang Technological UniversitySingapore 637551
Org. Lett.201618 (11), pp 2696–2699
DOI: 10.1021/acs.orglett.6b01160
Publication Date (Web): May 24, 2016
Copyright © 2016 American Chemical Society
*E-mail: cfliu@ntu.edu.sg.

link

https://pubs.acs.org/doi/abs/10.1021/acs.orglett.6b01160

hps://pubs.acs.org/doi/suppl/10.1021/acs.orgletttt.6b01160/suppl_file/ol6b01160_si_001.pdf

str3 str1 str2

 

Kalyan_Pasunooti2

 

Kalyan Kumar Pasunooti,

kalyan kumar <kalyandrf@gmail.com>

Dr. Kalyan Kumar Pasunooti pursued his PhD degree from Nanyang Technological University (NTU) (www.ntu.edu.sg), Singapore (2007 – 2011) in the field of Medicinal, Peptide & Protein chemistry. His graduate research work is focused on “Synthesis of bioactive amino acid building blocks and their applications towards the peptides and glycopeptides.” His have total 16 years of academic and industry experience with major multinationals companies & academic institutions and have worked with many collaborative professors around the globe. He authored with more than 28 international peer-reviewed high impact publications such as PNAS, Wily (Angew Chemie), RSC (Chem Comm and Org Biomol Chem), most of American Chemical Society journals (Journal of American Chemical Society, Org. Lett., ACS Chem Bio, J Comb Chem and Bioconugate Chem) and Elsevier (Tetrahedron Letters) journals which are featured many times in Chem. Eng. News and other journals. He holds American patent while work with Johns Hopkins-School of Medicine, USA and this molecule in phase II clinical trials for treating cancer.

Prior to his graduate studies, he spent 5 years as a research scientist in reputable research organizations namely GVK Bio, India (www.gvkbio.com) (2006-2007) and Dr. Reddy’s Laboratories Ltd (www.drreddys.com) (2003-2006) in India. After his PhD graduation, he worked for world leading research institutes such as Johns Hopkins-School of Medicine, USA (www.hopkinsmedicne.org) (2012-2013), Nanyang Technological University-NTU, Singapore) (www.ntu.edu.sg) (2013 – 2017) and Singapore MIT Alliance for research & Technology-SMART (www.smart.mit.edu) (2017–2018). His research interests focused on development of next generation biologically relevant peptide & protein therapeutics using their newly discovered methodologies for biomedical applications.

He has excellent skills in designing synthesis, purification and characterization of complex peptide and small molecules for medicinal chemistry applications. He gained extensive experience in Medicinal, Carbohydrate, Peptide & Protein and nucleotide & nucleoside Chemistry and familiar with modern methods and experienced in designing & executing synthesis for various bioactive peptide and small molecule inhibitors. He well versed in synthesis and characterization of complex organic molecules and with the analytical data interpretation.

 

Dr. Kalyan Kumar Pasunooti

Research Scientist at Singapore-MIT Alliance for Research & Technology Centre

Singapore’

Accomplished Peptide, Protein and Medicinal chemist with 16 years of academic and industrialexperience in the field of drug discovery and development. Specializations: Peptide & Protein Chemistry,Medicinal Chemistry (Drug Discovery and Development) and Chemical Biology.

ExperienceSingapore-MIT Alliance for Research & Technology Centre

Research Scientist

  • Company NameSingapore-MIT Alliance for Research & Technology Centre

    Dates EmployedJul 2017 – Present

    Employment Duration1 yr 4 mos

    LocationSingapore

    Medicinal Chemistry and Drug Discovery

  • Research Fellow

    Company NameNanyang Technological University, Singapore

    Dates EmployedOct 2013 – Jun 2017

    Employment Duration3 yrs 9 mos

    LocationSingapore

    Peptide & Protein Chemistry and Medicinal Chemistry

  • Postdoctoral Fellow

    Company NameJohns Hopkins Medicine

    Dates EmployedMay 2012 – Sep 2013

    Employment Duration1 yr 5 mos

    LocationBaltimore, Maryland Area

    Medicinal chemistry, Drug Discovery, Pharmacology and Chemical Biology

  • Postdoctoral Associate

    Company NameNanyang Technological University

    Dates EmployedJul 2011 – Mar 2012

    Employment Duration9 mos

    LocationSingapore

    Organic synthesis, Peptide & Carbohydrate chemistry and Medicinal chemistry.

  • Senior Research Associate in Medicinal Chemistry

    Company NameGVK Biosciences

    Dates EmployedJan 2007 – Jul 2007

    Employment Duration7 mos

    LocationHyderabad Area, India

    Synthesis of bioactive molecules for medicinal chemistry applications.

  • Junior Scientist in Medicinal Chemistry (Anti-Infective group)

    Company NameDr. Reddy’s Laboratories

    Dates EmployedAug 2003 – Dec 2006

    Employment Duration3 yrs 5 mos

    LocationHyderabad Area, India

    Medicinal chemistry (Anti-Infective group): My work entails design and synthesis of newoxazolidinone derivatives and new chemical entities as novel antibacterial agents. As a researchscientist my job demanded me to carry out extensive literature survey to design possible syntheticroutes for a proposed molecule and to carry out the total synthetic part in the laborator… See more

  • Education

    ////////

    READ

    ANTHONY MELVIN CRASTO

    https://newdrugapprovals.org/

    NDA

    DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO …..FOR BLOG HOME CLICK HERE

    Join me on Linkedin

    View Anthony Melvin Crasto Ph.D's profile on LinkedIn

    Join me on Facebook FACEBOOK

    Join me on twitterFollow amcrasto on Twitter
    Join me on google plus Googleplus

     amcrasto@gmail.com

    CALL +919323115463  INDIA

    //////////////

    Share

    4-(2-fluoro-4-nitrophenyl)morpholine

     Uncategorized  Comments Off on 4-(2-fluoro-4-nitrophenyl)morpholine
    Sep 202018
     

    str3 str4

    4-(2-fluoro-4-nitrophenyl)morpholine

    1H NMR (400MHz, CDCl3)  8.03 (ddd J=1.0, 2.6 and 9.0Hz, 1H, ArH), 7.94 (dd J=2.6 and 13.1Hz, 1H, ArH), 6.94 (t J=8.7Hz, 1H, ArH), 3.90 (t J=4.7Hz, 4H, 2xCH2O), 3.31 (m, 4H, 2xCH2N).

    13C NMR (100MHz, CDCl3)  153.3 (d J=249.5), 145.6 (d J=7.8Hz), 121.1 (d J=3.0Hz), 117.0 (d J=3.9Hz), 112.7 (d J=6.4Hz), 66.7, 50.0 (d J=4.9Hz).

    HRMS [M] Calcd for C10H11FN2O3 226.0748, Found 226.0749.

     

    Catalytic Static Mixers for the Continuous Flow Hydrogenation of a Key Intermediate of Linezolid (Zyvox)

    James GardinerXuan NguyenCharlotte GenetMike D. HorneChristian H. Hornung, and John Tsanaktsidis

    Org. Process Res. Dev., Article ASAP

    DOI: 10.1021/acs.oprd.8b00153

    ////////////////////

    Share

    3-fluoro-4- morpholinoaniline

     Uncategorized  Comments Off on 3-fluoro-4- morpholinoaniline
    Sep 202018
     

    STR1 STR2

    3-fluoro-4- morpholinoaniline
    1H NMR (400MHz, CDCl3)  6.82 (m, 1H, ArH), 6.43 (m, 2H, 2xArH), 3.87 (m, 4H, 2xCH2O), 3.58 (brs, 2H, NH2), 2.99 (m, 4H, 2xCH2N). 13C NMR (100MHz, CDCl3)  156.9 (d J= 245.4Hz), 143.0 (d J=10.4Hz), 131.8 (d J=9.7Hz), 120.4 (d J=4.2Hz), 110.8 (d J=3.0Hz), 104.0 (d J=23.8Hz), 67.3, 51.9 (d J=2.1Hz). HRMS [M] Calcd for C10H13FN2O 196.1006, Found 196.1004.
    Org. Process Res. Dev., Article ASAP
    DOI: 10.1021/acs.oprd.8b00153

     

    ////////////////////

    Share

    Crystallization

     Uncategorized  Comments Off on Crystallization
    Sep 122018
     

    Image result for Crystallization

    Crystallization is the (natural or artificial) process by which a solid forms, where the atoms or molecules are highly organized into a structure known as a crystal. Some of the ways by which crystals form are precipitating from a solutionfreezing, or more rarely depositiondirectly from a gas. Attributes of the resulting crystal depend largely on factors such as temperature, air pressure, and in the case of liquid crystals, time of fluid evaporation.

    Crystallization occurs in two major steps. The first is nucleation, the appearance of a crystalline phase from either a supercooled liquid or a supersaturated solvent. The second step is known as crystal growth, which is the increase in the size of particles and leads to a crystal state. An important feature of this step is that loose particles form layers at the crystal’s surface lodge themselves into open inconsistencies such as pores, cracks, etc.

    The majority of minerals and organic molecules crystallize easily, and the resulting crystals are generally of good quality, i.e. without visible defects. However, larger biochemical particles, like proteins, are often difficult to crystallize. The ease with which molecules will crystallize strongly depends on the intensity of either atomic forces (in the case of mineral substances), intermolecular forces (organic and biochemical substances) or intramolecular forces (biochemical substances).

    Crystallization is also a chemical solid–liquid separation technique, in which mass transfer of a solute from the liquid solution to a pure solid crystalline phase occurs. In chemical engineering, crystallization occurs in a crystallizer. Crystallization is therefore related to precipitation, although the result is not amorphous or disordered, but a crystal.

    The design of a successful crystallization process depends on choosing process parameters that will produce crystals of the required purity and yield, that can be isolated, filtered, and dried easily. Process parameters such as cooling rate, solvent composition, and agitation rate directly impact crystallization behavior. Scientists are tasked with understanding how these parameters will influence the outcome of the crystallization process. Often, process parameters for crystallization are chosen based on previous experience, and the outcome is determined by careful analysis of offline analytical data, such as particle size analysis, XRPD, or microscopy. This approach is common, but neglects to consider that crystallization occurs through a sequence of interdependent mechanisms which all contribute to the final outcome, and are each uniquely influenced by the choice of process parameters.

    Crystal nucleation and growth, phase separation, breakage, agglomeration, and polymorph transformations can occur separately, but also simultaneously, and are influenced by process parameters in unique ways. This convolution of mechanisms can mask the true role process parameters play in determining the outcome of a crystallization process, and make crystallization process design a particular challenge for scientists. In the absence of mechanistic understanding for crystallization processes, scientists must often rely on trial-and-error to adjust process parameters and optimize yield, purity, and particle size. This can be a time-consuming task and is one that rarely delivers crystals that can be isolated, filtered, and dried in a facile manner.

    In this series of articles, the most common crystallization mechanisms are described alongside strategies to optimize them. The complete guide to crystallization mechanisms can be downloaded here.

    What is Nucleation?

    Nucleation occurs when solute molecules assemble in a supersaturated solution and reach a critical size. Primary nucleation occurs when nuclei appear from a solution directly and secondary nucleation occurs when nulcei appear in the presence of solids. Nucleation is important to understand because the number and size of nuclei formed can have a dominant influence on the final outcome of the crystallization process. High nucleation rates can lead to excessive fines and a bimodal crystal population which can make product isolation, filtration, and further processing difficult.

    Considerations for Control

    The nucleation rate is dependent on the molecule being crystallized but can be manipulated by considering the solvent type, controlling the supersaturation level, and evaluating the role of impurities and mixing during crystallization design. Seeding is a common strategy deployed to control primary nucleation. Effective seeding can initiate nucleation at a consistent point, and by choosing the seed size and seed loading the nucleation rate can be controlled.

    Secondary nucleation often occurs during a crystallization process when supersaturation increases above a critical limit. This can occur when cooling is too fast or when anti-solvent is added quickly in an effort to increase yield. Secondary nucleation is particularly critical to understand and control because it can suddenly appear during scale-up when process parameters are controlled with less precision compared to the lab

    Key Crystallization Definitions

    Crystallization
    Crystallization is a process whereby solid crystals are formed from another phase, typically a liquid solution or melt.

    Crystal
    Crystal is a solid particle in which the constituent molecules, atoms, or ions are arranged in some fixed and rigid, repeating three-dimensional pattern or lattice.

    Precipitation
    Precipitation is another word for crystallization but is most often used when crystallization occurs very quickly through a chemical reaction.

    Solubility
    Solubility is a measure of the amount of solute that can be dissolved in a given solvent at a given temperature

    Saturated Solution
    At a given temperature, there is a maximum amount of solute that can be dissolved in the solvent. At this point the solution is saturated. The quantity of solute dissolved at this point is the solubility.

    Supersaturation
    Supersaturation is the difference between the actual solute concentration and the equilibrium solute concentration at a given temperature.

    Crystallization
    Process-of-Crystallization-200px.png
    Concepts
    Crystallization · Crystal growth
    Recrystallization · Seed crystal
    Protocrystalline · Single crystal
    Methods and technology
    Boules
    Bridgman–Stockbarger technique
    Crystal bar process
    Czochralski process
    Epitaxy
    Flux method
    Fractional crystallization
    Fractional freezing
    Hydrothermal synthesis
    Kyropoulos process
    Laser-heated pedestal growth
    Micro-pulling-down
    Shaping processes in crystal growth
    Skull crucible
    Verneuil process
    Zone melting
    Fundamentals
    Nucleation · Crystal
    Crystal structure · Solid

    Busting a myth about mechanochemical crystallization

    Adding varying amounts of liquid yields multiple crystal forms
    Chart and structures showing the different phases of caffeine and anthranilic acid cocrystals that are produced when different amounts of ethanol are added.
    Credit: Cryst. Growth Des.

    [+]Enlarge

    Chart and structures showing the different phases of caffeine and anthranilic acid cocrystals that are produced when different amounts of ethanol are added.
    Mechanochemical crystallization of caffeine and anthranilic acid yields polymorph I, polymorph II, or a mixture, depending on the amount of ethanol added.
    Credit: Cryst. Growth Des.

    Although it may seem counterintuitive to put a compound into a ball mill to turn it into a crystalline form, the approach nonetheless works—and adding varying amounts of liquid can determine the crystal form that results, reports a team led by Bill Jones of the University of Cambridge (Cryst. Growth Des.2016, DOI: 10.1021/acs.cgd.6b00682).

    Compounds of interest for materials and pharmaceuticals applications often crystallize into different forms, called polymorphs. Because polymorphs can have varying stability, solubility, and other properties, forming a specific polymorph can be critically important.

    Chemists have long thought that using one particular liquid when crystallizing compounds via mechanochemical milling always yields one particular polymorph. Seeking to test that dogma, Jones and coworkers crystallized 200 mg of a 1:1 equimolar mixture of caffeine and anthranilic acid using a ball mill, adding from 10 to 100 μL of 15 different liquids.

    Four liquids—acetonitrile, nitromethane, ethylene glycol, and 1,6-hexanediol—formed one polymorph each, regardless of the amount of liquid. The rest of the liquids yielded different polymorphs or mixtures, depending on liquid volume: 10 to 20 μL of ethanol formed polymorph II, for example, whereas 40 to 60 μL formed polymorph I. Additionally, 10 μL of 1-hexanol, 1-octanol, or 1-dodecanol formed polymorph III, a polymorph previously only prepared by desolvation.

    Similar effects could occur for single-component crystals, the authors say. The mechanism behind the phenomenon remains to be determined; the authors suggest that it could be a result of thermodynamic stabilization of nanoparticles, different growth mechanisms of the polymorphs, or changes in the free-energy difference between polymorphs caused by milling conditions.

    See also

    References

    1. Jump up^ Lin, Yibin (2008). “An Extensive Study of Protein Phase Diagram Modification:Increasing Macromolecular Crystallizability by Temperature Screening”. Crystal Growth & Design8 (12): 4277. doi:10.1021/cg800698p.
    2. Jump up^ Chayen, Blow (1992). “Microbatch crystallization under oil — a new technique allowing many small-volume crystallization trials”. Journal of Crystal Growth122 (1-4): 176-180. Bibcode:1992JCrGr.122..176Cdoi:10.1016/0022-0248(92)90241-A.
    3. Jump up^ Benvenuti, Mangani (2007). “Crystallization of soluble proteins in vapor diffusion for x-ray crystallography”. Nature Protocols2: 1663. doi:10.1038/nprot.2007.198.
    4. Jump up to:a b Tavare, N. S. (1995). Industrial Crystallization. Plenum Press, New York.
    5. Jump up to:a b McCabe & Smith (2000). Unit Operations of Chemical Engineering. McGraw-Hill, New York.
    6. Jump up^ “Crystallization”www.reciprocalnet.orgArchived from the original on 2016-11-27. Retrieved 2017-01-03.
    7. Jump up^ “Submerge Circulating Crystallizers – Thermal Kinetics Engineering, PLLC”Thermal Kinetics Engineering, PLLC. Retrieved 2017-01-03.
    8. Jump up^ “Draft Tube Baffle (DTB) Crystallizer – Swenson Technology”Swenson TechnologyArchived from the original on 2016-09-25. Retrieved 2017-01-03.

    Further reading

    • A. Mersmann, Crystallization Technology Handbook (2001) CRC; 2nd ed. ISBN0-8247-0528-9
    • Tine Arkenbout-de Vroome, Melt Crystallization Technology (1995) CRC ISBN1-56676-181-6
    • “Small Molecule Crystallization” (PDF) at Illinois Institute of Technology website
    • Glynn P.D. and Reardon E.J. (1990) “Solid-solution aqueous-solution equilibria: thermodynamic theory and representation”. Amer. J. Sci. 290, 164–201.
    • Geankoplis, C.J. (2003) “Transport Processes and Separation Process Principles”. 4th Ed. Prentice-Hall Inc.
    • S.J. Jancic, P.A.M. Grootscholten: “Industrial Crystallization”, Textbook, Delft University Press and Reidel Publishing Company, Delft, The Netherlands, 1984.

    External links

    Crystallization Publications

    Discover a selection of crystallization publications below:

    The seminal study on the nucleation of crystals from solution
    Jaroslav Nývlt, Kinetics of nucleation in solutions, Journal of Crystal Growth, Volumes 3–4, 1968.

    Excellent study on how crystals grow form solution
    Crystal Growth Kinetics, Material Science and Engineering, Volume 65, Issue 1, July 1984.

    An excellent description of the reasons solute-solvent systems exhibit oiling out instead of crystallization
    Kiesow et al., Experimental investigation of oiling out during crystallization process, Journal of Crystal Growth, Volume 310, Issue 18, 2008.

    Detailed examination of why agglomeration occurs during crystallization
    Brunsteiner et al., Toward a Molecular Understanding of Crystal Agglomeration, Crystal Growth & Design, 2005, 5 (1), pp 3–16.

    A study of breakage mechanisms during crystallization
    Fasoli & Conti, Crystal breakage in a mixed suspension crystallizer, Volume 8, Issue8, 1973, Pages 931-946.

    A great overview of how to design effective crystallization processes in the high value chemicals industry
    Paul et al., Organic Crystallization Processes, Powder Technology, Volume 150, Issue 2, 2005.

    Techniques to ensure the correct polymorph is crystallized every time
    Kitamura, Strategies for Control of Crystallization of Polymorphs, CrystEngComm, 2009,11, 949-964.

    ////////////////

    Share

    Elemental Impurities

     regulatory, Uncategorized  Comments Off on Elemental Impurities
    Jul 112018
     

    Image result for elemental impurities

    Elemental Impurities

    On January 1, 2018, new guidelines regarding elemental impurities in brand and generic drug products went into effect. Elemental impurities, such as arsenic and lead, pose toxicological risks to patients without providing any therapeutic benefit. These impurities may be present in drug products from a variety of sources, such as interactions with equipment during the drug manufacturing process.

    FDA, together with other organizations, such as the International Council for Harmonisation (ICH) and the U.S. Pharmacopeial Convention (USPC), have engaged in long-standing efforts to best protect patients from the risks posed by elemental impurities by developing limits for their amounts in drug products, and standardized approaches to use in determining the amount of elemental impurities in these products.

    As of January 1, 2018:

    • All new and existing NDAs and ANDAs for drug products with an official USP monograph are required to meet the requirements in USP General Chapters <232> and <233> for the control of elemental impurities.
    • Applicants submitting NDAs and ANDAs for drug products without a USP monograph are expected to follow the recommendations in the ICH Q3D Elemental Impuritiesdisclaimer icon guideline.


    Questions and Answers on Elemental Impurities
    :

    Why were these guidelines developed, and why are they important?

    Heavy metal elemental impurities pose serious risks to patients without providing a benefit. Modern methods provide better analytical tests to detect elemental impurities, which in turn, will help protect patients by ensuring approved products have safe levels of these impurities. The ICH guidelines and USP General Chapters <232>Elemental Impurities—Limits are focused on establishing Permitted Daily Exposures (PDEs) for elemental impurities in drug products. USP General Chapter <233>Elemental Impurities—Procedures describes analytical approaches for the detection of elemental impurities. The analytical approaches described in <233> are based on modern analytical capabilities, replace the outdated tests in the deleted USP General Chapter <231> Heavy Metals, and allow us to more precisely measure impurities to ensure safe levels. FDA, ICH, USP, and industry experts worked together to develop the new standards that are in alignment and help ensure high quality medicines.

    How has FDA been supporting industry to implement the requirements?

    FDA, ICH, and USP have all engaged with brand and generic drug manufacturers to support implementation of these requirements. These requirements are the result of long-standing efforts, and both ICH and USP included industry participants on their expert panels that developed these standards. With that input, an implementation date was identified that provided firms with substantial time to verify their operations met the requirements.

    In June 2016, FDA published a draft guidance, Elemental Impurities in Drug Products, to provide recommendations regarding the control of elemental impurities of human drug products. The draft guidance encouraged the early adoption of ICH Q3D guidelines and USP General Chapters <232> and <233> before the January 1, 2018 implementation date. FDA has also presented on this topic at conferences, including at a two-day ICH Q3D regional workshop it hosted in August 2016 1. These outreach efforts have supported efforts by industry to perform the risk assessments needed to implement the new guidelines in order to have complete, approvable applications. On an application-specific level, FDA began noting this requirement in complete response letters to applicants that contained quality deficiencies in Spring of 2017.

    What should companies do if they have questions about elemental impurity standards?

    Companies that have quality questions regarding elemental impurities and their applications should contact the Regulatory Business Process Manager (RBPM) in the Office of Program and Regulatory Operations, Office of Pharmaceutical Quality for their application. Applications that do not meet the elemental impurity guidelines are unable to be approved and applicants may receive a request for the information from the FDA in the form of an Information Request or a Complete Response letter. Firms should submit information on their elemental impurity risk assessments to FDA as soon as they are able, rather than waiting for a request from FDA, in order to minimize the impact on review and approval timeframes. The following resource may help applicants understand the process moving forward depending on where they are in the review process.

    What is the International Council for Harmonisation?

    ICH, first created in 1990 by regulatory agencies and both brand and generic drug manufacturing associations from the United States, Europe, and Japan, was established to facilitate international collaboration, and has been successful in standardizing and elevating drug development practices throughout the world. ICH’s mission helps to increase patient access to safe, effective, and high quality pharmaceuticals, and to ensure that pharmaceuticals are developed and registered efficiently. International harmonization of regulatory standards means that pharmaceutical manufacturers and developers will be held to the same standards in different markets (countries), which will make the development and delivery of quality pharmaceuticals to the public more timely and efficient. The ICH Website includes training modules on implementation of the Q3D elemental impurity guidelines.

    What is the U.S. Pharmacopeia Convention?

    The United States Pharmacopeia Convention (USPC) is a private non-profit organization that develops public standards related to pharmaceutical quality. USP General Chapters <232>Elemental Impurities—Limits, and, <233>Elemental Impurities—Procedures are applicable to compendial drug products as per Federal Food, Drug, and Cosmetic Act Sec. 201(j), and Sec. 501(b). USP’s website offers information regarding the history of actions they have taken on elemental impuritiesdisclaimer icon, as well as other FAQdisclaimer icon.


    1 Other presentations include the Drug Information Association’s CMC Workshop 2015disclaimer icon, the Consumer Healthcare Products Association’s 2015 Regulatory, Scientific & Quality Conferencedisclaimer icon, the Product Quality Research Institute (PQRI) / USP Workshop on ICH Q3D Elemental Impurities Requirementsdisclaimer icon, the Generic Pharmaceutical Association (now Association of Affordable Medicines) CMC Workshopdisclaimer icon, the USP Excipients Stakeholder Forum, the PQRI/USP Workshop on Implementation Status of ICH Q3Ddisclaimer icon, and the PQRI/USP Workshop on ICH Q3D Elemental Impurities Requirements – Recent Experience and Plans for Full Implementation in 2018disclaimer icon

    Elemental Impurities


    Efforts in this area are currently focused on three fronts:

    • Finalization of risk assessments to ensure compliance with the ICH Q3D guideline for all products supplied to those markets having implemented ICH Q3D and to the date for implementation

    • Continued development of ICH Q3D dermal limits

    • Removal of the heavy metals limit test USP <231>

    • Image result for elemental impurities
    • Image result for elemental impurities

    Marketed Product Compliance

    When it was published at the end of 2014, ICH Q3D(1) provided a 3 year moratorium in relation to established products, meaning that all such products would have to demonstrate compliance with the guideline at the end of 2017. Many involved will testify to the Herculean effort required to complete this within large organizations where hundreds if not thousands of products were within scope. What has been the outcome? Informal feedback within the industry is that aside from a small number of products, organizations have found that the vast majority of products assessed require no additional control measures because they already have appropriate quality control measures.

    Elemental Impurities within Excipients

    The ICH Q3D guideline describes how a risk-based approach to the control of elemental impurities in drug products can be taken, highlighting within this that assessments should be data-driven. Options in terms of data include both data generated specific to a drug product and published data. In 2015 the U.S. Food and Drug Administration (FDA) and the European International Pharmaceutical Excipient Council (IPEC) jointly published the outcome of a focused study on some 200 excipient samples covering a range of excipients. This concluded that the overall risk associated with excipients, including those that are mined, was relatively low, especially when typical proportions in formulated drug products were considered. With the express aim of building upon this initial study, a consortium of pharmaceutical companies has established a database to collate the results of analytical studies of the levels of elemental impurities within pharmaceutical excipients. This database currently includes the results of over 25 000 elemental determinations for over 200 different excipients and represents the largest known, and still rapidly expanding, collection of data of this type.
    Image result for elemental impurities
    A recently published analysis of the database(2) examined a series of aspects, including data coverage as well as impurity levels and variability (across supplier/grade, etc.). The database includes results from multiple analytical studies for many of the excipients and thus can give a clear indication of both excipient supplier and batch-to-batch variability as well as any variability associated with the different testing organizations and methods employed. The results are telling. Critically, the data confirm the findings of earlier, smaller FDA–IPEC studies showing that elemental impurity concentrations in excipients, including mined excipients, are generally low and when used in typical proportions in formulated drug products are unlikely to pose a significant patient safety risk.
    The database is now in active use within member organizations, providing real evidence in support of holistic ICH Q3D risk assessments and in the future potentially significantly reducing the need for testing. However, it is necessary to recognize that there was a sense that mined excipients could still present a risk over the long term. That variability in elemental impurity levels within mined excipients will vary over time, and further data will be required. There is therefore a need for continued collaboration between the pharmaceutical industry and excipient manufacturers.
    It is interesting to reflect that had such studies been conducted ahead of finalization of ICH Q3D, it is possible that it would have allowed us to eliminate concerns about elemental impurities, at least for some low-risk excipients Another study could have achieved the same outcome for manufacturing equipment.
    Image result for elemental impurities

    Removal of Heavy Metals Testing

    Perhaps our biggest challenge as an industry in this area relates to the potential to remove existing empirical testing for elemental impurities using the wet-chemistry heavy metals limit test because of differences in the global regulatory landscape. In the case of the United States Pharmacopeia (USP), this takes the form of the now-deleted USP Chapter <231>.
    On the basis of the time scale for implementation of ICH Q3D, most organizations are well-advanced in terms of the risk assessment of current products, as described above. In the clear majority of cases, this successfully demonstrates that the heavy metals test does not provide any additional control for elemental impurities. On this basis, it should therefore be possible to remove the heavy metals limit test, of which USP <231> is the most prevalent example.
    Image result for elemental impurities
    The situation in the U.S. is that removal is relatively straightforward, as the test has already been removed from the USP. A statement to confirm completion of an elemental impurity risk assessment is then provided in the product annual update. Elsewhere, the situation is more challenging. In Europe there is no definitive position, but filing a simple show-and-tell type 1A variation seems to provide a pathway. Thereafter, the situation is considerably more complex.
    In Japan, the equivalent of the USP <231> test has been retained in the Japanese Pharmacopeia (JP). Consequently, removing the test from an existing product (one where a monograph is published and it includes such a test) may require submitting a product-specific request to revise the individual monograph. It is also anticipated that removal of the test from approved but not monographed products will also require a post-approval change submission.
    In China, the Chinese Pharmacopeia (CP) will retain the test until at least 2020, and the indication is that the test should still be performed where registered.
    Image result for elemental impurities
    Outside of ICH regions, the situation is still more complicated. Given the prevalent position of the USP in many countries, API and product specifications often include USP <231>. However, this test no longer exists! The challenge then concerns whether the test can be removed and the specification revised, and if so, how this should be done. The scale of this is significant, especially if a formal variations procedure is needed. One apparent option is to continue testing, but even this is complicated, as it is not clear how one could continue to use a test that no longer exists in the USP. Some organizations have even considered developing a “USP <231>-like” test.
    Clearly, organizations do not want to continue to use an empirical test when a risk assessment has shown that it adds no value, but at present there is no obvious way to resolve this conundrum for globally marketed products until significant harmonization in compendial test requirements is achieved.
    Image result for elemental impuritiesImage result for elemental impuritiesImage result for elemental impurities
    REFERENCES
    1 Guideline for Elemental Impurities Q3D, Current Step 4 version, dated Dec 16, 2014.
    Boetzel, R.Ceszlak, A.Day, C.An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk AssessmentJ. Pharm. Sci. 2018DOI: 10.1016/j.xphs.2018.04.009
    //////////Elemental Impurities, ICH Q3D, USP
    Share

    ICH Q12: Guideline on Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management

     Uncategorized  Comments Off on ICH Q12: Guideline on Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
    Jul 062018
     

    Image result for ICH Q12

    ICH Q12: Guideline on Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, 1-2

    Image result for ICH Q12

    Recent ICH quality guidelines (Q8–Q11)(3−6) have focused on providing guidance on the development and manufacture of drug substances (Q11)(6) and drug products (Q8),(3) showing “baseline” and “enhanced” scientific approaches, and utilizing quality risk management tools (Q9) within the pharmaceutical quality management system (Q10). To further support the implementation of these development and manufacturing approaches, ICH recognized the value in providing tools and approaches for the management of post-approval chemistry, manufacturing, and controls (CMC) changes based on product and process understanding that could be employed by all ICH participants. Several useful tools had been established in different regions, and it was recognized that pharmaceutical innovation and continuous improvement would be optimally supported if best practices could be employed in similar ways across the regions. Achieving this harmonization would result in more efficient manufacture and change and would also increase the value of the pharmaceutical quality system and support continued optimization of the utilization of valuable resources within regulatory agencies and inspectorates (e.g., toward oversight of critical rather than noncritical changes, incentivizing industry’s understanding and management of manufacturing). The ICH Concept Paper for the development of this guidance was endorsed in 2014.(7)
    The drafted consensus document is now available for public comment (step 2 of the ICH process),(8) with comments being collected by the regions during 2018 (with various comment deadlines).
    The draft guidance includes some potentially very important approaches for future CMC change management, and importantly, the tools and approaches being developed are seen as usable across the range of pharmaceutical product types (including drug–device combinations) and applicable to existing products as well as newly approved products.
    An approach of particular importance that is included in the guideline is the “post-approval change management protocol” (PACMP), which allows for specific changes to be predescribed to regulators and agreement to be reached on the scientific approach and data expectations that will support the change. This ability to predefine how to successfully make a change will bring great clarity and predictability to the planning and prosecution of, particularly, complex change types (often viewed as major changes needing “prior approval” in current regulatory change systems). Furthermore, the predetermination of data necessary to support the change allows for the final communication of the change to be a simple matter of confirming the suitability of the change with the expected data and for the regulatory change class to be reduced on the basis of the prior agreement of the change management approach. Importantly, a PACMP can be either agreed for a single change for a single product or constructed and agreed in a more wide-ranging manner to support multiple similar changes to be conducted on more than one product. This is of immense potential value to industry and regulators alike. Annex II of the draft guideline provides illustrative examples of different types of PACMPs, giving an example of a PACMP for a single change (to a manufacturing site for a drug substance) and an example of the more general management of such a site change.
    In a section of the guideline on supporting post-approval changes for marketed products, where considerable manufacturing experience has been accrued, important approaches are given for the management of changes in analytical procedures and discussing how data requirements for changes (for stability data) can be impacted by product and process understanding.
    In addition, the guidance seeks to provide an approach to differentiate the levels of regulatory oversight of particular changes on the basis of known impact and criticality of the potential change to product quality. The ability to differentiate change expectations on the basis of actual product understanding is a natural extension of the approaches taken in ICH Q8 and Q11, where for example product and process understanding can establish a “Design Space” for manufacturing and control within which changes are not seen as requiring regulatory oversight. In the draft of Q12, this concept is further developed by the concept of “Established Conditions” (ECs), with discussion of how investment in understanding can impact submission expectations (with Appendix I of the draft guideline providing an illustration of CTD sections that contain ECs and Annex I suggesting illustrative examples of ECs for both chemical products and biological products) and post-approval change management expectations. Importantly, the guidance discusses how this approach could be used for existing products, where the manufacturing process may have been described without any differentiation of change management expectations, leading to inefficient use of both industry and regulatory resources.
    The draft guideline also includes a suggested system for the collation of such “agreed” regulatory change mechanisms for a product via use of a product lifecycle management (PLCM) approach, wherein the agreed changes can be clearly collated alongside the manufacturing commitments and the agreed (lesser) change reporting category for the changes. Annex III of the draft documentation provides an example of a PLCM document.
    The guideline also contains content describing the pharmaceutical quality system (PQS) change management expectations (with Appendix II of the guideline providing further illustration of principles of change management) and the relationship between industry and regulators and importantly between regulatory assessment and inspection needed to support strong implementation of the approaches within Q12.
    The draft guideline clearly already provides tools and approaches for change management of immense potential value. Nevertheless, the opportunity to comment on the draft is always an important step in the development of an ICH guideline, and it is important to ensure that comments assist in providing the clearest possible final guidance that will be readily and consistently implemented to mutual industry and regulator benefit. It is noteworthy that the current draft of the guideline includes wording suggesting that some concepts may not be implementable at the current time across every region. It will be of greatest benefit if the tools and approaches as described and agreed in the finalized guidance will be available for use on as wide a global basis as possible, in line with the ongoing vision of ICH for science-based, harmonized, and efficient regulation of pharmaceuticals.
    Image result for ICH Q12
    3  Pharmaceutical Development Q8(R2), Current Step 4 version, dated August 2009.
    4 Quality Risk Management Q9, Current Step 4 version, dated Nov 9, 2005.
    5 Pharmaceutical Quality System Q10, Current Step 4 version, dated June 4, 2008.
    6 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) Q11, Current Step 4 version, dated May 1 2012.
    7 Final Concept Paper Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, dated July 28 2014, endorsed by the ICH Steering Committee on Sept 9, 2014.
    8 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Q12, draft version endorsed on Nov 16, 2017.

     

    ////////////////ICH Q12, Guideline, Technical and Regulatory Considerations, Pharmaceutical Product, Lifecycle Management

    Share

    Amelioration of diethylnitrosamine (DEN)-induced hepatocellular carcinogenesis in animal models via knockdown oxidative stress and proinflammatory markers by Madhuca longifolia embedded silver nanoparticles

     nanotechnology, Uncategorized  Comments Off on Amelioration of diethylnitrosamine (DEN)-induced hepatocellular carcinogenesis in animal models via knockdown oxidative stress and proinflammatory markers by Madhuca longifolia embedded silver nanoparticles
    Jun 122018
     

    str1

    Amelioration of diethylnitrosamine (DEN)-induced hepatocellular carcinogenesis in animal models via knockdown oxidative stress and proinflammatory markers by Madhuca longifolia embedded silver nanoparticles

    http://pubs.rsc.org/en/content/articlepdf/2018/ra/c7ra12775h

    DOI: 10.1039/c7ra12775h

    rsc.li/rsc-advances

    RSC Adv., 2018, 8, 6940–6953

    Deepika Singh, a Manvendra Singh,b Ekta Yadav,a Neha Falls,a Ujendra Komal,c Deependra Singh Dangi,d Vikas Kumare and Amita Verma*f

     

    Department of Pharmaceutical Science, Faculty of Health Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Allahabad, 211007, India

    b HMFA Institute of Engineering & Technology, Handia, Allahabad, 211007, India

    c Department of Mechanical & Industrial Engineering, Indian Institute of Technology, Roorkee, Uttrakhand, India

    d Kinapse India Scientic Services Pvt. Ltd., Gurgoan, Haryana, India

    e Natural Product Drug Discovery Laboratory, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, Uttar Pradesh 211007, India

    f Bio-organic & Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad – 211007, Uttar Pradesh, India.

    E-mail: amitaverma.dr@gmail.com; amita.verma@shiats.edu.in

     

    In hepatocellular carcinoma (HCC), primary liver cancer is primarily responsible for inflammation-related cancer as more than 90% of HCCs emerge with regard to hepatic damage and inflammation. Tenacious inflammation is known to advance and intensify liver tumours. Nanomaterials, for example, silver nanoparticles synthesized from plant-derived materials have shown great outcomes in reducing the precancerous nodules and have anticancer properties. The aim of the present investigation was to biosynthesize, characterize and evaluate the anticancer activity of nanoparticles-embedded Madhuca longifolia extract (MLAgNPs) on an experimental model of hepatic cancer in rats. M. longifolia contains a high amount of flavonoids and other phenolic derivative. The silver nanoparticles synthesized by M. longifolia were characterized by various instruments, including UV-Vis spectrophotometry, X-ray beam diffraction, field-emission scanning electron microscopy with energy dispersive X-ray analysis, transmission electron microscopy and Fourier transform infrared spectroscopy. Liver cancer was induced to 36 Wistar rats by a single dose of diethylnitrosamine (DEN) (200 mg kg1 BW). Hepatic cancer by MLAgNPs dose-dependently limited macroscopical variation compared with the DEN-induced hepatic cancer groups. The serum and liver were taken to measure the antioxidant parameters, proinflammatory cytokines and for a histopathological study. Serum hepatic and serum non-hepatic along with inflammatory cytokines were also assessed. Reduction in the levels of proinflammatory cytokines, namely tumour necrosis factor-a, interleukin-6, interleukin-1b, nuclear factor kappa beta (NF-kB), and improved membrane-bound enzyme activity were also detected. It was found that minor morphological anomalies were identified in the histopathology analysis in the MLAgNPs-treated groups. It could be concluded that silver nanoparticles introduce an extraordinary potential for use as adjuvants in hepatic cancer treatment because of their antioxidant abilities and ability to diminish inflammation in liver tissue by attenuating the NF-kB pathway.

    Conclusion Our outcomes have demonstrated that the bioengineered silver nanoparticles of M. longifolia leaves extract cause in vitro and in vivo apoptosis of hepatic cancer through an ROS pathway and are promising agents in liver carcinogenesis.

     

    AMITA

    DR AMITA VERMA

    Bio-organic & Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad – 211007, Uttar Pradesh, India.

    E-mail: amitaverma.dr@gmail.com; amita.verma@shiats.edu.in

     

    Sam Higginbottom University of Agriculture, Technology and Sciences

     

    //////////////

    Share

    Expansion of First-in-Class Drug Candidates That Sequester Toxic All-Trans-Retinal and Prevent Light-Induced Retinal Degeneration s

     Uncategorized  Comments Off on Expansion of First-in-Class Drug Candidates That Sequester Toxic All-Trans-Retinal and Prevent Light-Induced Retinal Degeneration s
    Jun 042018
     

    str1

     

    ABSTRACT All-trans-retinal, a retinoid metabolite naturally produced upon photoreceptor light activation, is cytotoxic when present at elevated levels in the retina. To lower its toxicity, two experimentally validated methods have been developed involving inhibition of the retinoid cycle and sequestration of excess of all-trans-retinal by drugs containing a primary amine group. We identified the first-in-class drug candidates that transiently sequester this metabolite or slow down its production by inhibiting regeneration of the visual chromophore, 11-cis-retinal. Two enzymes are critical for retinoid recycling in the eye. Lecithin:retinol acyltransferase (LRAT) is the enzyme that traps vitamin A (all-trans-retinol) from the circulation and photoreceptor cells to produce the esterified substrate for retinoid isomerase (RPE65), which converts all-trans-retinyl ester into 11-cis-retinol. Here we investigated retinylamine and its derivatives to assess their inhibitor/substrate specificities for RPE65 and LRAT, mechanisms of action, potency, retention in the eye, and protection against acute light-induced retinal degeneration in mice. We correlated levels of visual cycle inhibition with retinal protective effects and outlined chemical boundaries for LRAT substrates and RPE65 inhibitors to obtain critical insights into therapeutic properties needed for retinal preservation.

    http://molpharm.aspetjournals.org/content/early/2014/12/23/mol.114.096560

    Expansion of First-in-class Drug Candidates that Sequester Toxic All-trans-retinal and Prevent Light-induced Retinal Degeneration

    Jianye ZhangZhiqian DongSreenivasa MundlaX Eric HuWilliam SeibelRuben PapoianKrzysztof Palczewski and Marcin Golczak

     

     

    str1

    Sreeni Labs Private Limited, Hyderabad, India is ready to take up challenging synthesis projects from your preclinical and clinical development and supply from few grams to multi-kilo quantities. Sreeni Labs has proven route scouting ability  to  design and develop innovative, cost effective, scalable routes by using readily available and inexpensive starting materials. The selected route will be further developed into a robust process and demonstrate on kilo gram scale and produce 100’s of kilos of in a relatively short time.

    Accelerate your early development at competitive price by taking your route selection, process development and material supply challenges (gram scale to kilogram scale) to Sreeni Labs…………

    INTRODUCTION

    Sreeni Labs based in Hyderabad, India is working with various global customers and solving variety of challenging synthesis problems. Their customer base ranges from USA, Canada, India and Europe. Sreeni labs Managing Director, Dr. Sreenivasa Reddy Mundla has worked at Procter & Gamble Pharmaceuticals and Eli Lilly based in USA.

    The main strength of Sreeni Labs is in the design, development of innovative and highly economical synthetic routes and development of a selected route into a robust process followed by production of quality product from 100 grams to 100s of kg scale. Sreeni Labs main motto is adding value in everything they do.

    They have helped number of customers from virtual biotech, big pharma, specialty chemicals, catalog companies, and academic researchers and drug developers, solar energy researchers at universities and institutions by successfully developing highly economical and simple chemistry routes to number of products that were made either by very lengthy synthetic routes or  by using highly dangerous reagents and Suzuki coupling steps. They are able to supply materials from gram scale to multi kilo scale in a relatively short time by developing very short and efficient synthetic routes to a number of advanced intermediates, specialty chemicals, APIs and reference compounds. They also helped customers by drastically reducing number of steps, telescoping few steps into a single pot. For some projects, Sreeni Labs was able to develop simple chemistry and avoided use of palladium & expensive ligands. They always begin the project with end in the mind and design simple chemistry and also use readily available or easy to prepare starting materials in their design of synthetic routes

    Over the years, Sreeni labs has successfully made a variety of products ranging from few mg to several kilogram scale. Sreeni labs has plenty of experience in making small select libraries of compounds, carbocyclic compounds like complex terpenoids, retinal derivatives, alkaloids, and heterocyclic compounds like multi substituted beta carbolines, pyridines, quinolines, quinolones, imidazoles, aminoimidazoles, quinoxalines, indoles, benzimidazoles, thiazoles, oxazoles, isoxazoles, carbazoles, benzothiazoles, azapines, benzazpines, natural and unnatural aminoacids, tetrapeptides, substituted oligomers of thiophenes and fused thiophenes, RAFT reagents, isocyanates, variety of ligands,  heteroaryl, biaryl, triaryl compounds, process impurities and metabolites.

    Sreeni Labs is Looking for any potential opportunities where people need development of cost effective scalable routes followed by quick scale up to produce quality products in the pharmaceutical & specialty chemicals area. They can also take up custom synthesis and scale up of medchem analogues and building blocks.  They have flexible business model that will be in sink with customers. One can test their abilities & capabilities by giving couple of PO based (fee for service) projects.

    Some of the compounds prepared by Sreeni labs;

    str1str1

    str1str1

    str1str1

    str1str1

    str1str1

    str1str1

    See presentation below

    LINK ON SLIDESHARE

    Managing Director at Sreeni Labs Private Limited

    Few Case Studies : Source SEEENI LABS

    QUOTE………….

    One virtual biotech company customer from USA, through a common friend approached Sreeni Labs and told that they are buying a tetrapeptide from Bachem on mg scale at a very high price and requested us to see if we can make 5g. We accepted the challenge and developed solution phase chemistry and delivered 6g and also the process procedures in 10 weeks time. The customer told that they are using same procedures with very minor modifications and produced the tetrapeptide ip to 100kg scale as the molecule is in Phase III.

    One East coast customer in our first meeting told that they are working with 4 CROs of which two are in India and two are in China and politely asked why they should work with Sreeni Labs. We told that give us a project where your CROs failed to deliver and we will give a quote and work on it. You pay us only if we deliver and you satisfy with the data. They immediately gave us a project to make 1.5g and we delivered 2g product in 9 weeks. After receiving product and the data, the customer was extremely happy as their previous CRO couldn’t deliver even a milligram in four months with 3 FTEs.

    One Midwest biotech company was struggling to remove palladium from final API as they were doing a Suzuki coupling with a very expensive aryl pinacol borane and bromo pyridine derivative with an expensive ligand and relatively large amount of palldium acetate. The cost of final step catalyst, ligand and the palladium scavenging resin were making the project not viable even though the product is generating excellent data in the clinic. At this point we signed an FTE agreement with them and in four months time, we were able to design and develop a non suzuki route based on acid base chemistry and made 15g of API and compared the analytical data and purity with the Suzuki route API. This solved all three problems and the customer was very pleased with the outcome.

    One big pharma customer from east coast, wrote a structure of chemical intermediate on a paper napkin in our first meeting and asked us to see if we can make it. We told that we can make it and in less than 3 weeks time we made a gram sample and shared the analytical data. The customer was very pleased and asked us to make 500g. We delivered in 4 weeks and in the next three months we supplied 25kg of the same product.

    Through a common friend reference, a European customer from a an academic institute, sent us an email requesting us to quote for 20mg of a compound with compound number mentioned in J. med. chem. paper. It is a polycyclic compound with four contiguous stereogenic centers.  We gave a quote and delivered 35 mg of product with full analytical data which was more pure than the published in literature. Later on we made 8g and 6g of the same product.

    One West coast customer approached us through a common friend’s reference and told that they need to improve the chemistry of an advanced intermediate for their next campaign. At that time they are planning to make 15kg of that intermediate and purchased 50kg of starting raw material for $250,000. They also put five FTEs at a CRO  for 5 months to optimize the remaining 5 steps wherein they are using LAH, Sodium azide,  palladium catalyst and a column chromatography. We requested the customer not to purchase the 50kg raw material, and offered that we will make the 15kg for the price of raw material through a new route  in less than three months time. You pay us only after we deliver 15 kg material. The customer didn’t want to take a chance with their timeline as they didn’t work with us before but requested us to develop the chemistry. In 7 weeks time, we developed a very simple four step route for their advanced intermediate and made 50g. We used very inexpensive and readily available starting material. Our route gave three solid intermediates and completely eliminated chromatographic purifications.

    One of my former colleague introduced an academic group in midwest and brought us a medchem project requiring synthesis of 65 challenging polyene compounds on 100mg scale. We designed synthetic routes and successfully prepared 60 compounds in a 15 month time.  

    UNQUOTE…………

    The man behind Seeni labs is Dr.Sreenivasa  Reddy Mundla

    Sreenivasa Reddy

    Dr. Sreenivasa Reddy Mundla

    Managing Director at Sreeni Labs Private Limited

    Sreeni Labs Private Limited

    Road No:12, Plot No:24,25,26

    • IDA, Nacharam
      Hyderabad, 500076
      Telangana State, India

    Links

    LINKEDIN https://in.linkedin.com/in/sreenivasa-reddy-10b5876

    FACEBOOK https://www.facebook.com/sreenivasa.mundla

    RESEARCHGATE https://www.researchgate.net/profile/Sreenivasa_Mundla/info

    EMAIL mundlasr@hotmail.com,  Info@sreenilabs.com, Sreeni@sreenilabs.com

    Dr. Sreenivasa Mundla Reddy

    Dr. M. Sreenivasa Reddy obtained Ph.D from University of Hyderabad under the direction Prof Professor Goverdhan Mehta in 1992. From 1992-1994, he was a post doctoral fellow at University of Wisconsin in Professor Jame Cook’s lab. From 1994 to 2000,  worked at Chemical process R&D at Procter & Gamble Pharmaceuticals (P&G). From 2001 to 2007 worked at Global Chemical Process R&D at Eli Lilly and Company in Indianapolis. 

    In 2007  resigned to his  job and founded Sreeni Labs based in Hyderabad, Telangana, India  and started working with various global customers and solving various challenging synthesis problems. 
    The main strength of Sreeni Labs is in the design, development of a novel chemical route and its development into a robust process followed by production of quality product from 100 grams to 100’s of kg scale.
     

    They have helped number of customers by successfully developing highly economical simple chemistry routes to number of products that were made by Suzuki coupling. they are able to shorten the route by drastically reducing number of steps, avoiding use of palladium & expensive ligands. they always use readily available or easy to prepare starting materials in their design of synthetic routes.

    Sreeni Labs is Looking for any potential opportunities where people need development of cost effective scalable routes followed by quick scale up to produce quality products in the pharmaceutical & specialty chemicals area. They have flexible business model that will be in sink with customers. One can test their abilities & capabilities by giving PO based projects

    Experience

    Founder & Managing Director

    Sreeni Labs Private Limited

    August 2007 – Present (8 years 11 months)

    Sreeni Labs Profile

    Sreeni Labs Profile

    View On SlideShare

    Principal Research Scientist

    Eli Lilly and Company

    March 2001 – August 2007 (6 years 6 months)

    Senior Research Scientist

    Procter & Gamble

    July 1994 – February 2001 (6 years 8 months)

    Education

    University of Hyderabad

    Doctor of Philosophy (Ph.D.), 
    1986 – 1992

    PUBLICATIONS

    Article: Expansion of First-in-Class Drug Candidates That Sequester Toxic All-Trans-Retinal and Prevent Light-Induced Retinal Degeneration

    Jianye Zhang · Zhiqian Dong · Sreenivasa Reddy Mundla · X Eric Hu · William Seibel ·Ruben Papoian · Krzysztof Palczewski · Marcin Golczak

    Article: ChemInform Abstract: Regioselective Synthesis of 4Halo ortho-Dinitrobenzene Derivative

    Sreenivasa Mundla

    Aug 2010 · ChemInform

    Article: Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-β Receptor Type I Inhibitor as Antitumor Agent

    Hong-yu Li · William T. McMillen · Charles R. Heap · Denis J. McCann · Lei Yan · Robert M. Campbell · Sreenivasa R. Mundla · Chi-Hsin R. King · Elizabeth A. Dierks · Bryan D. Anderson · Karen S. Britt · Karen L. Huss

    Apr 2008 · Journal of Medicinal Chemistry

    Article: ChemInform Abstract: A Concise Synthesis of Quinazolinone TGF-β RI Inhibitor Through One-Pot Three-Component Suzuki—Miyaura/Etherification and Imidate—Amide Rearrangement Reactions

    Hong-yu Li · Yan Wang · William T. McMillen · Arindam Chatterjee · John E. Toth ·Sreenivasa R. Mundla · Matthew Voss · Robert D. Boyer · J. Scott Sawyer

    Feb 2008 · ChemInform

    Article: ChemInform Abstract: A Concise Synthesis of Quinazolinone TGF-β RI Inhibitor Through One-Pot Three-Component Suzuki—Miyaura/Etherification and Imidate—Amide Rearrangement Reactions

    Hong-yu Li · Yan Wang · William T. McMillen · Arindam Chatterjee · John E. Toth ·Sreenivasa R. Mundla · Matthew Voss · Robert D. Boyer · J. Scott Sawyer

    Nov 2007 · Tetrahedron

    Article: Dihydropyrrolopyrazole Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: A Novel Benzimidazole Series with Selectivity versus Transforming Growth Factor-β Type II Receptor Kinase and Mixed Lineage Kinase-7

    Hong-yu Li · Yan Wang · Charles R Heap · Chi-Hsin R King · Sreenivasa R Mundla · Matthew Voss · David K Clawson · Lei Yan · Robert M Campbell · Bryan D Anderson · Jill R Wagner ·Karen Britt · Ku X Lu · William T McMillen · Jonathan M Yingling

    Apr 2006 · Journal of Medicinal Chemistry

    Read full-textSource

    Article: Studies on the Rh and Ir mediated tandem Pauson–Khand reaction. A new entry into the dicyclopenta[ a, d]cyclooctene ring system

    Hui Cao · Sreenivasa R. Mundla · James M. Cook

    Aug 2003 · Tetrahedron Letters

    Article: ChemInform Abstract: A New Method for the Synthesis of 2,6-Dinitro and 2Halo6-nitrostyrenes

    Sreenivasa R. Mundla

    Nov 2000 · ChemInform

    Article: ChemInform Abstract: A Novel Method for the Efficient Synthesis of 2-Arylamino-2-imidazolines

    Read at

    [LINK]

    Patents by Inventor Dr. Sreenivasa Reddy Mundla

    • Patent number: 7872020

      Abstract: The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro -4H-pyrrolo[1,2-b]pyrazole monohydrate.

      Type: Grant

      Filed: June 29, 2006

      Date of Patent: January 18, 2011

      Assignee: Eli Lilly and Company

      Inventor: Sreenivasa Reddy Mundla

    • Publication number: 20100120854

      Abstract: The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate.

      Type: Application

      Filed: June 29, 2006

      Publication date: May 13, 2010

      Applicant: ELI LILLY AND COMPANY

      Inventor: Sreenivasa Reddy Mundla

    • Patent number: 6066740

      Abstract: The present invention provides a process for making 2-amino-2-imidazoline, guanidine, and 2-amino-3,4,5,6-tetrahydroyrimidine derivatives by preparing the corresponding activated 2-thio-subsituted-2-derivative in a two-step, one-pot procedure and by further reacting yields this isolated derivative with the appropriate amine or its salts in the presence of a proton source. The present process allows for the preparation of 2-amino-2-imidazolines, quanidines, and 2-amino-3,4,5,6-tetrahydropyrimidines under reaction conditions that eliminate the need for lengthy, costly, or multiple low yielding steps, and highly toxic reactants. This process allows for improved yields and product purity and provides additional synthetic flexibility.

      Type: Grant

      Filed: November 25, 1997

      Date of Patent: May 23, 2000

      Assignee: The Procter & Gamble Company

      Inventors: Michael Selden Godlewski, Sean Rees Klopfenstein, Sreenivasa Reddy Mundla, William Lee Seibel, Randy Stuart Muth

    TGF-β inhibitors

    US 7872020 B2

    Sreenivasa Reddy Mundla

    The present invention provides 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl) -5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate, i.e., Formula I.

    Figure US07872020-20110118-C00002

    EXAMPLE 1 Preparation of 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl-5,6-dihydro-4H -pyrrolo[1,2-b]pyrazole monohydrate

    Figure US07872020-20110118-C00008

    Galunisertib

    1H NMR (CDCl3): δ=9.0 ppm (d, 4.4 Hz, 1H); 8.23-8.19 ppm (m, 2H); 8.315 ppm (dd, 1.9 Hz, 8.9 Hz, 1H); 7.455 ppm (d, 4.4 Hz, 1H); 7.364 ppm (t, 7.7 Hz, 1H); 7.086 ppm (d, 8.0 Hz, 1H); 6.969 ppm (d, 7.7 Hz, 1H); 6.022 ppm (m, 1H); 5.497 ppm (m, 1H); 4.419 ppm (t, 7.3 Hz, 2H); 2.999 ppm (m, 2H); 2.770 ppm (p, 7.2 Hz, 7.4 Hz, 2H); 2.306 ppm (s, 3H); 1.817 ppm (m, 2H). MS ES+: 370.2; Exact: 369.16

    ABOVE MOLECULE IS

    https://newdrugapprovals.org/2016/05/04/galunisertib/

    Galunisertib

    Phase III

    LY-2157299

    CAS No.700874-72-2

    READ MY PRESENTATION ON

    Accelerating Generic Approvals, see how you can accelerate your drug development programme

    Accelerating Generic Approvals by Dr Anthony Crasto

    KEYWORDS   Sreenivasa Mundla Reddy, Managing Director, Sreeni Labs Private Limited, Hyderabad, Telangana, India,  new, economical, scalable routes, early clinical drug development stages, Custom synthesis, custom manufacturing, drug discovery, PHASE 1, PHASE 2, PHASE 3,  API, drugs, medicines

    ////////////

    Share

    Specific Stereoisomeric Conformations Determine the Drug Potency of Cladosporin Scaffold against Malarial Parasite

     Uncategorized  Comments Off on Specific Stereoisomeric Conformations Determine the Drug Potency of Cladosporin Scaffold against Malarial Parasite
    May 272018
     

     

    STR4

    SR1

    SR2

     

    Specific Stereoisomeric Conformations Determine the Drug Potency of Cladosporin Scaffold against Malarial Parasite

    https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00565

    Pronay Das†ab, Palak Babbar†c, Nipun Malhotra†c, Manmohan Sharmac , Goraknath R. Jachakab , Rajesh G. Gonnadebd, Dhanasekaran Shanmugambe, Karl Harlosf , Manickam Yogavelc , Amit Sharmac *, and D. Srinivasa Reddyab* †All three have contributed equally to this work.
    aOrganic Chemistry Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411008, India
    b Academy of Scientific and Innovative Research (AcSIR), New Delhi 110025, India
    cMolecular Medicine Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi 110067, India dCenter for Material Characterization, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411008, India
    e Biochemical Sciences Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411008, India
    fDivision of Structural Biology, Welcome Trust Centre for Human Genetics, The Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK
    J. Med. Chem., Just Accepted Manuscript
    DOI: 10.1021/acs.jmedchem.8b00565
    Publication Date (Web): May 21, 2018
    Copyright © 2018 American Chemical Society
    The dependence of drug potency on diastereomeric configurations is a key facet. Using a novel general divergent synthetic route for a three-chiral centre anti-malarial natural product cladosporin, we built its complete library of stereoisomers (cladologs) and assessed their inhibitory potential using parasite-, enzyme- and structure-based assays.
    We show that potency is manifest via tetrahyropyran ring conformations that are housed in the ribose binding pocket of parasite lysyl tRNA synthetase (KRS). Strikingly, drug potency between top and worst enantiomers varied 500-fold, and structures of KRS-cladolog complexes reveal that alterations at C3 and C10 are detrimental to drug potency where changes at C3 are sensed by rotameric flipping of Glutamate332.
    Given that scores of anti-malarial and anti-infective drugs contain chiral centers, this work provides a new foundation for focusing on inhibitor stereochemistry as a facet of anti-microbial drug development.
    Cladosporin (12) displays exquisite selectivity for the parasite lysyl-tRNA synthetase over human enzyme. This species specific selectivity of cladosporin has been previously described through comprehensive sequence alignment, where the residues val329 and ser346 seem to be sterically crucial for accommodating the methyl moiety of THP ring10. The structural features of compound 12 clearly indicate the presence of three stereocenters, and therefore 2n (n=3) i.e., eight stereoisomers are possible (Fig.1). Till date, only one asymmetric total synthesis of cladosporin13 has been achieved which was followed by another report of formal syntheses14. Here, we have developed a general chemical synthesis route to synthetically access all the eight possible stereoisomers of compound 12.
    cladosporin (compound 12) (0.052 g) as a white solid with a yield of 54 %. Melting point: 171-173 °C; [α]25 D = -15.75 (c = 0.6, EtOH); IR υmax(film): cm-1 3416, 3022, 1656, 1218; 1H NMR (400 MHz, CDCl3): δ 11.06 (s, 1H), 7.47 (br. s., 1H), 6.29 (s, 1H), 6.16 (s, 1H), 4.68 (t, J = 9.8 Hz, 1H), 4.12 (s, 1H), 4.01 (s, 1H), 2.89 – 2.75 (m, 2H), 2.00 – 1.94 (m, 1H), 1.87 – 1.81 (m, 1H), 1.70 – 1.63 (m, 4H), 1.35 (d, J = 6.1 Hz, 2H), 1.23 (d, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 169.9, 164.3, 163.1, 141.8, 106.7, 102.0, 101.5, 76.3, 68.0, 66.6, 39.3, 33.6, 30.9, 18.9, 18.1; HRMS calculated for C16H21O5 [M + H]+ 293.1384, observed 293.1379.
    STR1

    STR2

     

    Dr. D. Srinivasa Reddy has been appointed as an editor of Bioorganic & Medicinl Chemistry Letters, Elsevier Publications. Congratulation Sir !

    Click here for details. https://www.journals.elsevier.com/bioorganic-and-medicinal-chemistry-letters

    The research interests of his group lie in issues related to application of oriented organic synthesis, in particular total synthesis of biologically active natural products, medicinal chemistry and crop protection. This team has been credited with having accomplished total synthesis of more than 25 natural products with impressive biological activities. “Some of our recent achievements include identification of potential leads, like antibiotic compound based on hunanamycin natural product for treating food infections, anti-diabetic molecule in collaboration with an industry partner and  anti-TB compound using a strategy called ‘re-purposing of a drug scaffold’,” said Reddy.

    A total of two awardees out of four were from CSIR institutes. In addition to Reddy, Rajan Shankarnarayanan, CSIR – CCMB, Hyderabad (basic sciences), also was conferred with the award. Vikram Mathews, CMC, Vellore (medical research) and Prof Ashish Suri, AIIMS, New Delhi (clinical research), were the others to receive the awards.

    With more than 80 scientific publications and 35 patents, Reddy is one of the most prominent scientists in the city and has already been honoured with the Shanti Swarup Bhatnagar prize in chemical sciences. Reddy is also a nominated member of the scientific body of Indian Pharmacopoeia, government of India and was  elected as a fellow of the Telangana and Maharashtra Academies of Sciences in addition to the National Academy of Sciences, India (NASI).

    //////////CLADOSPORIN, NCL, CSIR, SRINIVASA REDDY, PUNE, MALARIA
    Share

    What are the drugs of the future?

     Uncategorized  Comments Off on What are the drugs of the future?
    May 032018
     

    A cartoon representing how, in history, we are continuously faced with new scientific advancements that make us question what the future holds and whether what we currently have is still useful or should be replaced.

    Med. Chem. Commun., 2018, Advance Article
    DOI: 10.1039/C8MD90019A, Opinion
    Huy X. Ngo, Sylvie Garneau-Tsodikova
    Are small molecules or biologics the drugs of the future?

    What are the drugs of the future?

    Author affiliations

    Abstract

    Are small molecules or biologics the drugs of the future? Small-molecule drugs have historically been the pillars of traditional medicine. However, recently, we seem to be amidst a scientific revolution with the rise of many FDA-approved biologic drugs. This opinion article looks at the current state of small molecules and biologics and assesses what the future holds for these two broad classes of drugs.

    Are small molecules or biologics the drugs of the future? Let’s think about this… (Fig. 1). For many of us growing up in the 20th century, videotapes were fixtures of our childhoods. In the current entertainment industry, videotapes have completely become obsolete and been replaced by more complex and sophisticated Blu-ray Discs, which deliver ultra high-definition pictures and films to viewers. Technological change is inevitable in our society, which embraces innovations. Similarly, the pharmaceutical industry has been experiencing its own scientific revolution, as more and more novel biologic drugs continue to emerge. Are these biologics the Blu-ray Discs of the pharmaceutical industry? Will smallmolecule drugs fade into history like videotapes did? In an attempt to address these questions, we will compare and contrast small-molecule and biologic drugs to assess what roles they will serve in our healthcare system in the future

    ////////////
    Share
    Follow

    Get every new post on this blog delivered to your Inbox.

    Join other followers: